Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution
King, A. T.
Rutherford, S. A.
Lloyd, S. K.
Freeman, S. R.
Pathmanaban, O. N.
Thomas, O. M.
Laitt, R. D.
Kilday, J. P.
McBain, Catherine A
Smith, M. J.
Harkness, E. F.
Evans, D. G.
AffiliationManchester Centre for Genomic Medicine, Manchester Academic Health Science Centre, Division of Evolution and Genomic Medicine, University of Manchester, St Mary's Hospital, Manchester Universities NHS Foundation Trust, Manchester,
MetadataShow full item record
AbstractBackground: Limited data exists on the disease course of Neurofibromatosis Type 2 (NF2) to guide clinical trial design. Methods: A prospective database of patients meeting NF2 diagnostic criteria, reviewed between 1990-2020, was evaluated. Follow-up to first vestibular schwannoma (VS) intervention and death was assessed by univariate analysis and stratified by age at onset, era referred and inheritance type. Interventions for NF2-related tumours were assessed. Cox regression was performed to determine the relationship between individual factors from time of diagnosis to NF2-related death. Results: Three-hundred-and-fifty-three patients were evaluated. During 4643.1 follow-up years from diagnosis to censoring 60 patients (17.0%) died. The annual mean number of patients undergoing VS surgery or radiotherapy declined, from 4.66 and 1.65 respectively per 100 NF2 patients in 1990-1999 to 2.11 and 1.01 in 2010-2020, as the number receiving bevacizumab increased (2.51 per 100 NF2 patients in 2010-2020). Five patients stopped bevacizumab to remove growing meningioma or spinal schwannoma. 153/353 (43.3%) had at least one neurosurgical intervention/radiation treatment within 5 years of diagnosis. Patients asymptomatic at diagnosis had longer time to intervention and better survival compared to those presenting with symptoms. Those symptomatically presenting <16 and >40 years had poorer overall survival than those presenting at 26-39 years (P=0.03 and P=0.02 respectively) but those presenting between 16-39 had shorter time to VS intervention. Individuals with de novo constitutional variants had worse survival than those with de novo mosaic or inherited disease (P=0.004). Conclusion: Understanding disease course improves prognostication, allowing for better informed decisions about care.
CitationForde C, King AT, Rutherford SA, Hammerbeck-Ward C, Lloyd SK, Freeman SR, et al. Disease course of Neurofibromatosis Type 2; a 30-year follow-up study of 353 patients seen at a single institution. Neuro Oncol. 2020.
- Clinical course of vestibular schwannoma in pediatric neurofibromatosis Type 2.
- Authors: Choi JW, Lee JY, Phi JH, Wang KC, Chung HT, Paek SH, Kim DG, Park SH, Kim SK
- Issue date: 2014 Jun
- Trends in phenotype in the English paediatric neurofibromatosis type 2 cohort stratified by genetic severity.
- Authors: Halliday D, Emmanouil B, Vassallo G, Lascelles K, Nicholson J, Chandratre S, Anand G, Wasik M, Pretorius P, Evans DG, Parry A, English NF2 research group.
- Issue date: 2019 Aug
- Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.
- Authors: Sun S, Liu A
- Issue date: 2014 Dec
- Neurofibromatosis type 2.
- Authors: Slattery WH
- Issue date: 2015 Jun
- Pediatric cerebellopontine angle and internal auditory canal tumors: clinical article..
- Authors: Holman MA, Schmitt WR, Carlson ML, Driscoll CL, Beatty CW, Link MJ
- Issue date: 2013 Oct